Acute Myeloid Leukemia Real World Treatment Patterns
Among patients with a diagnosis of AML who received non-intensive chemotherapy:

* Describe patient demographic and clinical characteristics
* Describe treatment patterns
* Describe effectiveness outcomes
* Evaluate tumor response
Leukemia, Myeloid, Acute
DRUG: azacitidine|DRUG: venetoclax|DRUG: glasdegib
Overall Survival, Overall survival was the duration from diagnosis of disease to death., January 1, 2012 to January 10, 2020|Event Free Survival, Time from the treatment initiation date to the date of treatment failure (TF), relapse from CR or better, or death from any cause, whichever comes first, January 1, 2012 to January 10, 2020|Relapse Free Survival, Time from the treatment initiation date to the date of a relapse event, or death from any cause, whichever comes first, January 1, 2012 to January 10, 2020|Best response, Best response recorded from treatment start until disease progression/recurrence, January 1, 2012 to January 10, 2020|Time to best response, Time from treatment initiation until best response recorded, January 1, 2012 to January 10, 2020|Duration of best response, Time from best response achieved until lose of response or the end of the record, whichever occurs first, January 1, 2012 to January 10, 2020
Among patients with a diagnosis of AML who received non-intensive chemotherapy:

* Describe patient demographic and clinical characteristics
* Describe treatment patterns
* Describe effectiveness outcomes
* Evaluate tumor response